Study wrapper · #208
Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry.
Editor's note
An anti-doping detection-method paper, not an efficacy study. Researchers developed and validated a liquid-chromatography mass-spectrometry method to extract and detect eight GHRPs — including ipamorelin, hexarelin, and GHRP-6 — from human urine, focusing on the intact peptides plus the one well-characterised GHRP-2 metabolite. The clinical framing in the abstract is worth noting only as context: these peptides are orally active and raise the body's own growth-hormone output, which is precisely why they evade standard exogenous-GH testing and why detection tools are needed. Proof-of-principle used urine after a single 10 mg oral dose of GHRP-2, where the metabolite was detectable to 20 hours while the parent was not. This is forensic surveillance work; ipamorelin, hexarelin, and GHRP-6 appear only as analytes. It offers no efficacy, safety, or dosing information for people. The human-outcome evidence for these compounds lies elsewhere and remains limited.
Plain-language abstract
This study built and tested a laboratory method to detect growth-hormone-releasing peptides — including ipamorelin, hexarelin, and GHRP-6 — in human urine for anti-doping control. These peptides can be taken by mouth and prompt the body to make more of its own growth hormone, which means the usual test for injected growth hormone misses them, so dedicated detection methods are needed. The researchers worked out how to efficiently extract eight of these compounds from urine and identify them using liquid chromatography with mass spectrometry. Because the breakdown products of most of these peptides were still unknown, the method focused on detecting the intact peptides, plus the one known major breakdown product of GHRP-2. They validated the method on standard quality measures and then tested it on real urine from a person given a single 10 mg oral dose of GHRP-2: the known breakdown product was detectable for over 20 hours, though the original peptide was not. This is a detection-method study only and does not examine any health benefit or side effect of these peptides.